Main Article Content
Miglitol is a secondâ€generation â€glycosidase inhibitor with a chemical structure of 1â€desoxynojiromycin. It acts as a
potent competitive inhibitor of the alfa glycosidase in the microvilli of the intestinal brush border. Miglitol has a shortÂ biological halfâ€life (2 h) and its bioavailability is >90%. Moreover, the site of absorption of miglitol is in the intestine.Therefore,Â the objective of the present work is to develop a sustained release matrix drug delivery systemfor the drug miglitol for theÂ better management of the disease, to minimize sideâ€effects as well as to improve patient compliance using different grades ofÂ HPMC Kâ€4, HPMC Kâ€15 and HPMC Kâ€100 in different proportions and combinations by the direct compression technique.
Key words: Bioavailability, controlled release, direct compression technique, hydrophilic polymer, miglitol
This is an Open Access article distributed under the terms of the Attribution-Noncommercial 4.0 International License [CC BY-NC 4.0], which requires that reusers give credit to the creator. It allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, for noncommercial purposes only.